Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 1, 2016, Pages 27-31

  Riaz, Nadeem ^a   Sherman, Eric ^b   Koutcher, Lawrence ^a   Shapiro, Lauren ^a   Katabi, Nora ^b   Zhang, Zhigang ^b   Shi, Weiji ^b   Fury, Mathew ^b   Wong, Richard ^a   Wolden, Suzanne ^a   Rao, Shyam ^a   Lee, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Medical Oncology ^*  (United States)

Author keywords

Cetuximab; Cisplatin; Head and neck cancer; HPV; Radiation

Indexed keywords

CETUXIMAB; CISPLATIN; PROTEIN P16; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; WART VIRUS; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; HEAD AND NECK NEOPLASMS; HYPOPHARYNGEAL NEOPLASMS; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; LARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VIROLOGY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84957844436     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000006     Document Type: Article

References (21)

1. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
2. Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23:2708-2714.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
6. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009; 92:4-14.
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
8. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25:2191-2197.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
10. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
11. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81:915-922.
12. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
13. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. ASCO Annual Meeting Chicago, IL. 2011;29.
14. Ley J, Mehan P, Wildes TM, et al. Concurrent Cisplatin versus Vetuximab with Definitive Radiation Therapy (RT) for Head and Neck Squamous Cell Carcinoma (HNSCC): A Retrospective Comparison. Multidisciplinary Head and Neck Cancer Symposium. Phoenix, AZ. 2012.
15. Shapiro LQ, Sherman EJ, Koutcher L, et al. Efficacy of concurrent cetuximab (C225) versus (vs.) 5-fluorouracil/carboplatin (5 FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC). ASCO Annual Meeting Chicago, IL 2012.
16. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;71:676-681.
17. Levy AR, Johnston KM, Sambrook J, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin. 2011;27:2253-2259.
18. Vermorken JB, Stohlmacher J, Oliner KS, et al. Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (-) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): analysis of the phase 3 SPECTRUM trial. The European Multidisciplinary Cancer Congress. Stockholm, Sweden. 2011.
19. Seiwert T, Fayette J, Cupissol D, et al. A Randomized, Open-label, Phase II Study of Afatinib (bibw 2992) Versus Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck-Final Data. Multidisciplinary Head and Neck Cancer Symposium. Phoenix, AZ2012.
20. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100:33-40.
21. Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98:38-41.